# US 2023/0272012 A1 · Peptides and methods of use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0272012 A1 - Document ID: US20230272012A1 - Status: Published application - Kind: A1 - Application number: 18/034,731 - Filed: 2021-11-01 - Published: 2023-08-31 - Earliest claimed: 2020-11-02 - Assignees: Realta Life Sciences, Inc. - Applicants: Realta Life Sciences, Inc. - Inventors: Neel K. KRISHNA; Kenji CUNNION - Web page: https://patentgrep.com/patent/US20230272012A1 ## CPC - C07K 14/001: {by chemical synthesis} - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention provides synthetic peptides. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human astrovirus protein. In some embodiments, the invention is directed to peptides that are modifications of PA including sarcosine substitutions at certain amino acid positions that are stapled and/or have D-enantiomeric substitutions of certain amino acids. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions. ## Claims ### Claim 1 A synthetic peptide comprising at least about 95% sequence identity to an amino acid sequence selected from the group of SEQ ID NO: 6-55. ### Claim 2 (depends on 1) The synthetic peptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 6-55. ### Claim 3 (depends on 1) The synthetic peptide of claim 1 comprising at least about 95% sequence identity to amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 22, 25. ### Claim 4 (depends on 1) The synthetic peptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 22, and 25. ### Claim 5 (depends on 1) The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 9. ### Claim 6 (depends on 1) The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 19. ### Claim 7 (depends on 1) The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 22. ### Claim 8 (depends on 1) The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 25. ### Claim 9 (depends on 1) A composition comprising at least one synthetic peptide of claim 1, optionally in further combination with another D-enantiomeric and/or stapled peptide form of SEQ ID NO: 4 and/or SEQ ID NO: 5, and variants thereof, and/or one or more of SEQ ID NO: 2, 3, 4, and/or 5, and variants thereof. ### Claim 10 (depends on 1) A pharmaceutical composition comprising a therapeutically effective amount of at least one synthetic peptide of claim 1, and optionally at least one pharmaceutically acceptable carrier, diluent, or excipient. ### Claim 11 (depends on 10) A method of regulating the complement system comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 12 (depends on 10) A method of inhibiting myeloperoxidase activity comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 13 (depends on 10) A method of inhibiting NETosis comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 14 (depends on 10) A method of inhibiting oxidant activity comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 15 (depends on 10) A method of inhibiting PD-1 binding to PD-L1 comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 16 (depends on 10) A method of inhibiting T cell exhaustion comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 17 (depends on 10) A method of inhibiting angiogenesis comprising administering the pharmaceutical composition of claim 10 to a subject in need thereof. ### Claim 18 (depends on 9) A pharmaceutical composition comprising a therapeutically effective amount of the composition of claim 9, and optionally at least one pharmaceutically acceptable carrier, diluent, or excipient.